Literature DB >> 15862426

Positron emission tomography-measured abnormal responses of myocardial blood flow to sympathetic stimulation are associated with the risk of developing cardiovascular events.

Thomas H Schindler1, Egbert U Nitzsche, Heinrich R Schelbert, Manfred Olschewski, James Sayre, Michael Mix, Ingo Brink, Xiao-Li Zhang, Michael Kreissl, Nobuhisa Magosaki, Hanjoerg Just, Ulrich Solzbach.   

Abstract

OBJECTIVES: We sought to assess prospectively whether patients with normal coronary angiograms but with impaired myocardial blood flow (MBF) increases to cold pressor testing (CPT) are at increased risk for cardiovascular events.
BACKGROUND: Invasive angiographic assessments of coronary vasomotor function have demonstrated an impairment of endothelium-related coronary flow increases to independently predict future cardiovascular events. It is unknown whether noninvasive positron emission tomography (PET)-measured MBF alterations to sympathetic stimulation with CPT are associated with the risk of developing cardiovascular events.
METHODS: A total of 72 patients (44 men, 28 women, age 58 +/- 8 years) referred for diagnostic cardiac catheterization were studied. Myocardial blood flow was measured in absolute units with (13)N-ammonia using PET, at baseline and during CPT in each patient. Cardiovascular events (cardiovascular death, acute coronary syndrome, myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, ischemic stroke, or peripheral revascularization) were assessed as clinical outcome parameters over a mean follow-up period of 66 +/- 8 months. Patients were assigned to three groups: group 1, patients with >/=40% increase in MBF (%DeltaMBF), n = 22; group 2, patients with >0 and <40% increases in MBF, n = 32; and group 3, patients with decreases in MBF (</=0%), n = 18.
RESULTS: During follow-up, one of the group 1 patients developed a cerebral stroke. In group 2, 15 cardiovascular events occurred in 9 patients and in group 3, 7 patients experienced 9 cardiovascular events (p </= 0.0001, univariate by log-rank test). Impaired MBF increases in group 2 and group 3 were associated with a significantly higher incidence of cardiovascular events by Kaplan-Meier analysis (p = 0.033, log-rank test). After adjusting for known coronary risk factors, MBF responses to CPT revealed a nonsignificant trend to be independently associated with a higher incidence for cardiovascular events (p = 0.065, multivariate by Cox regression model).
CONCLUSIONS: Noninvasive PET-measured impaired MBF increases to sympathetic stimulation are associated with the risk of developing cardiovascular events.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15862426     DOI: 10.1016/j.jacc.2005.01.040

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  61 in total

1.  Intra- and inter-operator repeatability of myocardial blood flow and myocardial flow reserve measurements using rubidium-82 pet and a highly automated analysis program.

Authors:  Ran Klein; Jennifer M Renaud; Maria C Ziadi; Stephanie L Thorn; Andy Adler; Rob S Beanlands; Robert A deKemp
Journal:  J Nucl Cardiol       Date:  2010-04-13       Impact factor: 5.952

2.  Early insights of cardiac risk and treatment response with quantitative PET monitoring of coronary-specific endothelial dysfunction and myocardial perfusion reserve.

Authors:  Ronald G Schwartz
Journal:  J Nucl Cardiol       Date:  2010-12       Impact factor: 5.952

Review 3.  Quantification of myocardial blood flow and flow reserve: Technical aspects.

Authors:  Ran Klein; Rob S B Beanlands; Robert A deKemp
Journal:  J Nucl Cardiol       Date:  2010-08       Impact factor: 5.952

4.  Long-term smoking causes more advanced coronary endothelial dysfunction in middle-aged smokers compared to young smokers.

Authors:  Masanao Naya; Koichi Morita; Keiichiro Yoshinaga; Osamu Manabe; Daisuke Goto; Kenji Hirata; Chietsugu Katoh; Nagara Tamaki; Hiroyuki Tsutsui
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-11-24       Impact factor: 9.236

5.  Quantitative analysis of coronary endothelial function with generator-produced 82Rb PET: comparison with 15O-labelled water PET.

Authors:  Keiichiro Yoshinaga; Osamu Manabe; Chietsugu Katoh; Li Chen; Ran Klein; Masanao Naya; Robert A deKemp; Kathryn Williams; Rob S B Beanlands; Nagara Tamaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-07-13       Impact factor: 9.236

6.  Myocardial blood flow: Putting it into clinical perspective.

Authors:  Thomas Hellmut Schindler
Journal:  J Nucl Cardiol       Date:  2015-12-28       Impact factor: 5.952

Review 7.  Clinical use of quantitative cardiac perfusion PET: rationale, modalities and possible indications. Position paper of the Cardiovascular Committee of the European Association of Nuclear Medicine (EANM).

Authors:  Roberto Sciagrà; Alessandro Passeri; Jan Bucerius; Hein J Verberne; Riemer H J A Slart; Oliver Lindner; Alessia Gimelli; Fabien Hyafil; Denis Agostini; Christopher Übleis; Marcus Hacker
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-02-05       Impact factor: 9.236

8.  Partial volume correction incorporating Rb-82 positron range for quantitative myocardial perfusion PET based on systolic-diastolic activity ratios and phantom measurements.

Authors:  Nils P Johnson; Stefano Sdringola; K Lance Gould
Journal:  J Nucl Cardiol       Date:  2010-12-24       Impact factor: 5.952

9.  Improvement in coronary vascular dysfunction produced with euglycaemic control in patients with type 2 diabetes.

Authors:  T H Schindler; A D Facta; J O Prior; J Cadenas; W A Hsueh; M J Quinones; H R Schelbert
Journal:  Heart       Date:  2006-08-29       Impact factor: 5.994

10.  Endothelial dysfunction in patients with antiphospholipid syndrome assessed with positron emission tomography.

Authors:  Erick Alexanderson; Patricio Cruz; Angélica Vargas; Aloha Meave; Alejandro Ricalde; Jose A Talayero; José Luis Romero-Ibarra; Tovë M Goldson; Olga L Vera-Lastra; Gabriela Medina; Luis Jara; Mary-Carmen Amigo
Journal:  J Nucl Cardiol       Date:  2007-07-02       Impact factor: 5.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.